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Background: We studied the role of caspase-2 in apoptosis induction by taxanes (paclitaxel, novel taxane SB-T-1216)
in breast cancer cells using SK-BR-3 (nonfunctional p53, functional caspase-3) and MCF-7 (functional p53, nonfunctional
caspase-3) cell lines.
Results: Both taxanes induced apoptosis in SK-BR-3 as well as MCF-7 cells. Caspase-2 activity in SK-BR-3 cells increased
approximately 15-fold within 48 h after the application of both taxanes at the death-inducing concentration (100 nM).
In MCF-7 cells, caspase-2 activity increased approximately 11-fold within 60 h after the application of taxanes (300 nM).
Caspase-2 activation was confirmed by decreasing levels of procaspase-2, increasing levels of cleaved caspase-2 and
the cleavage of caspase-2 substrate golgin-160. The inhibition of caspase-2 expression using siRNA increased the
number of surviving cells more than 2-fold in MCF-7 cells, and at least 4-fold in SK-BR-3 cells, 96 h after the application
of death-inducing concentration of taxanes. The inhibition of caspase-2 expression also resulted in decreased cleavage
of initiator caspases (caspase-8, caspase-9) as well as executioner caspases (caspase-3, caspase-7) in both cell lines after
the application of taxanes. In control cells, caspase-2 seemed to be mainly localized in the nucleus. After the
application of taxanes, it was released from the nucleus to the cytosol, due to the long-term disintegration of the
nuclear envelope, in both cell lines. Taxane application led to some formation of PIDDosome complex in both cell lines
within 24 h after the application. After taxane application, p21WAF1/CIP1 expression was only induced in MCF-7 cells with
functional p53. However, taxane application did not result in a significant increase of PIDD expression in either SK-BR-3
or MCF-7 cells. The inhibition of RAIDD expression using siRNA did not affect the number of surviving SK-BR-3 and
MCF-7 cells after taxane application at all.
Conclusion: Caspase-2 is required, at least partially, for apoptosis induction by taxanes in tested breast cancer cells. We
suggest that caspase-2 plays the role of an apical caspase in these cells. Caspase-2 seems to be activated via other
mechanism than PIDDosome formation. It follows the release of caspase-2 from the nucleus to the cytosol.
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Taxanes represent a well-known but relatively new group
of anticancer drugs. There are two established (classical)
taxanes, paclitaxel (Taxol®) and docetaxel (Taxotere®), cur-
rently used for treatment of breast and ovarian cancer as
well as head and neck, lung and prostate cancer [1,2]. In
addition to the aforementioned classical taxanes, novel
taxanes have been developed. They represent a new gene-
ration of taxoids (taxane analogs). They are not yet used* Correspondence: jan.kovar@lf3.cuni.cz
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reproduction in any medium, provided the orin clinical practice but they are substantially more effective
in resistant cancer cells in vitro and in vivo [3-7].
Taxanes are mitotic poisons. They bind to the β subunit
of the tubulin heterodimer, thereby stabilizing microtu-
bules and inhibiting their depolymerization [8-10]. In this
way, taxanes are thought to block progression through the
M-phase of the cell cycle [9,11]. However, the relationship
between mitotic arrest and the induction of cell death by
taxanes remains unclear [12-14].
The molecular mechanism of cell death induction by
taxanes is not fully understood either. It has beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to be p53 independent [4,15]. On the other hand, several
findings concerning cytochrome c release, caspase-9 acti-
vation and caspase-3 activation strongly indicate, that at
least in some cases, a mitochondrial pathway is involved
in apoptosis induction by taxanes [4,16,17]. However,
alternative nonmitochondrial pathways could also be in-
volved [4,7,18], including caspase-8 activation [7,14,19].
Recently, the role of caspase-2 in apoptosis induction by
taxanes has come under consideration [7,14,20,21].
Caspase-2 is ubiquitously expressed and represents an
evolutionarily highly conserved mammalian caspase. How-
ever, its precise physiological function has not been identi-
fied. Several lines of evidence point to caspase-2 as a major
player in apoptosis induction [22,23]. Procaspase-2 inter-
acts with other proteins, such as CARD-containing RAIDD
protein, via its caspase recruitment domain (CARD).
RAIDD interacts with another death domain containing
protein PIDD via its death domain [24]. The complex of
procaspase-2, RAIDD and PIDD, known as PIDDosome,
facilitates caspase-2 activation. PIDD is a p53-inducible
protein [23,25]. In some cases, PIDD seems to function as
a regulator of caspase-2 activity [26]. However, caspase-2
activation independent of p53, as well as RAIDD and
PIDD, has also been reported, e.g. in cases of cell death via
a mitotic catastrophe [27-30]. Caspase-2 has been found in
the cytosol, Golgi complex and mitochondria. It is also
present in the nucleus. Active caspase-2 specifically cleaves
golgin-160 which is present in the Golgi complex [31].
It has been suggested that caspase-2 functions as the
most apical caspase when apoptosis is induced by DNA
damage and cytotoxic stress [32,33]. The involvement of
caspase-2 activation in apoptosis of breast cancer cells, in-
duced by various stimuli, has also been found [27,34-36].
Several other studies have also demonstrated caspase-2
activation in various types of cancer cells following apop-
tosis induction by taxanes [21,37,38].
We have previously found that caspase-2 is signifi-
cantly activated in breast cancer cells (together with the
activation of caspase-3, caspase-9 and caspase-8) follo-
wing apoptosis induction by taxanes [7,14]. We have
also shown that the mitochondrial pathway is not, at
least in some cases, the predominant pathway of apop-
tosis induction by taxanes in breast cancer cells, and
that caspase-2 may be a major player in this process
[7]. In our present study, we investigated the role of
caspase-2 in apoptosis induction by taxanes in breast
cancer cells. We used breast cancer cells SK-BR-3
(nonfunctional p53, functional caspase-3) and MCF-7
(functional p53, nonfunctional caspase-3) as an expe-
rimental model and tested both classical (paclitaxel)
and novel (SB-T-1216) taxanes. We demonstrated that
caspase-2 is required for apoptosis induction by taxanes
in the tested breast cancer cells, probably as an apicalcaspase. Caspase-2 is activated via other mechanism
than PIDDosome formation.
Results
Effect of taxanes on growth and survival
The effects of paclitaxel and SB-T-1216 on growth and
survival of SK-BR-3 cells were tested over a wide range of
concentrations (0.3-1000 nM). Paclitaxel and SB-T-1216
both induced death of SK-BR-3 cells within 96 h of incu-
bation at a concentration of 30 nM and higher concentra-
tions. The C50 values (concentration of taxanes resulting
in 50% living cells compared to controls after 96 h of in-
cubation) were 15 nM and 3 nM for paclitaxel and SB-
T-1216, respectively (Figure 1).
In the case of MCF-7, the effects of taxanes were also
tested over a wide range of concentrations (0.3-3000 nM).
Both paclitaxel and SB-T-1216 induced the death of MCF-
7 cells within 96 h of incubation at a concentration of 100
nM and higher concentrations. The C50 values of pacli-
taxel and SB-T-1216 were similar, 5 nM and 8 nM, re-
spectively (Figure 1).
The data showed that MCF-7 cells were more resistant
to cell death induction by both taxanes at higher concen-
trations (30 nM and higher concentrations) than SK-BR-3
cells. In MCF-7 cells, paclitaxel and SB-T-1216 exerted
similar effects. However, in SK-BR-3 cells, SB-T-1216
seemed to be more efficient than paclitaxel (Figure 1).
On the basis of our data, we selected 100 nM and 300
nM as the cell death-inducing concentrations, i.e. the lo-
west concentration having complete death-inducing effect,
of tested taxanes for SK-BR-3 cells and MCF-7 cells, re-
spectively. These concentrations were used in subsequent
experiments.
Effect of taxanes on caspase-2 activity
Employing a commercial kit and flow cytometry (see
“Materials and Methods”), we tested the time course of
caspase-2 activation in both SK-BR-3 and MCF-7 cells
after taxane application.
Caspase-2 activity in SK-BR-3 cells increased within
48 h after the application of paclitaxel and SB-T-1216 at
death-inducing concentrations (100 nM) approximately
16-fold and 14-fold, respectively. A substantial increase
(approximately 10-fold for both taxanes) was seen 36 h
after taxane application as well as a noticeable increase
(about 3-fold) 24 h after application (Figure 2).
In the case of MCF-7 cells, caspase-2 activity increased
within 60 h after the application of both taxanes at death-
inducing concentrations (300 nM) approximately 11-fold. A
significant increase (approximately 4-fold for both taxanes)
was seen 48 h after taxane application and a noticeable in-
crease (about 2-fold) 36 h after application (Figure 2).
In order to confirm caspase-2 activation, we assessed
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Figure 1 Effect of paclitaxel and SB-T-1216 (0.3-3000 nM) on the growth and survival of SK-BR-3 and MCF-7 cells. Control cells (C) were
incubated without taxane. The cells were seeded at 20×103 cells/100 µl of medium per well. The number of cells of the inoculum is shown as a
dotted line. The number of living cells was determined after 96 h of incubation (see “Materials and Methods“). Each column represents the mean
of 8 separate cultures ± SEM.
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http://www.cancerci.com/content/13/1/42procaspase-2 using western blot analysis. Procaspase-2
level decreased significantly 36 h after the application of
both taxanes in SK-BR-3 cells. After 48 h, the level of
procaspase-2 in SK-BR-3 cells was very low (Figure 3A).
Concerning MCF-7 cells, some decrease in procaspase-2
level was seen 24 h after taxane application, but a more
significant decrease was seen 36 h and 48 h after appli-
cation. After 60 h, the level of procaspase-2 in MCF-7
cells was very low (Figure 3A).
Decreasing procaspase-2 level points at procaspase-2
cleavage resulting from formation of active caspase-2.
The decrease of procaspase-2 level in SK-BR-3 cells cor-
related with increased level of the cleaved form 36 h
after taxane application. However, 48 h after taxane
application cleaved caspase-2 disappeared (Figure 3A).
Similarly, the decrease of procaspase-2 level in MCF-7
cells correlated with increased level of the cleaved form
36 h and 48 h after taxane application. Again, 60 h after
taxane application we can see decreasing level of cleaved
caspase-2 (Figure 3A).
The levels of caspase-2 substrate golgin-160 using
western blot analysis were also assessed. A significant de-
crease in golgin-160 level corresponded with decreased
procaspase-2 level in both SK-BR-3 and MCF-7 cells after
application of both taxanes (Figure 3A,B).Effect of the inhibition of caspase-2 expression on taxane
induced cell death
Employing RNA interference (see “Materials andMethods”),
we assessed the effect of specific inhibition of caspase-2
expression on cell death induction after taxane application.
First, the efficiency of the RNA interference was tested.
The inhibition of caspase-2 expression was about 80%
compared to control (Figure 4A) in SK-BR-3 cells and
more than 80% in MCF-7 cells (Figure 4A). Moreover,
nonsense siRNA or specific caspase-2 siRNA did not sig-
nificantly affect cell growth or survival in either cell line.
However, cells transfected with siRNAs seemed to grow
slightly slowlier in comparison with control (Figure 4B).
After 48 h of incubation with taxanes at death-inducing
concentrations (100 nM), the inhibition of caspase-2 ex-
pression resulted in an approximately 2-fold increase in
the number of surviving SK-BR-3 cells. It represents a
statistically significant increase from 26% to 60% of the
original number of cells for paclitaxel and from 33% to
64% for SB-T-1216. After 96 h, the effect was even more
pronounced. In the case of paclitaxel, the number of sur-
viving SK-BR-3 cells increased from 4% to 30% and from
7% to 26% for SB-T-1216 (Figure 4C).
As for MCF-7 cells, the inhibition of caspase-2 expres-
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Figure 2 Effect of paclitaxel and SB-T-1216 on the activity of caspase-2 in SK-BR-3 and MCF-7 cells. After 0, 12, 24, 36, 48 and 60 h of
incubation with paclitaxel or SB-T-1216 (100 nM for SK-BR-3 cells and 300 nM for MCF-7 cells), the activity of caspase-2 was measured by flow
cytometry employing CaspGLOWTM Active Caspase Staining Kit (see “Materials and Methods“). Mean fluorescence at 0 h was 23.9 for SK-BR-3
cells and 28.5 for MCF-7 cells. Each column represents the mean of 2 experimental values ± SEM. *P < 0.05, **P < 0.01 when comparing the
effect with that at 0 h.
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http://www.cancerci.com/content/13/1/42at death-inducing concentrations (300 nM), increased the
number of surviving cells roughly 2-fold after 48 h and
96 h of incubation. After 48 h of incubation, there was a
statistically significant increase from 96% to 203% of the
original number of cells for paclitaxel and from 78% to
147% for SB-T-1216. After 96 h, the number of surviving
cells increased from 42% to 112% and from 50% to 121%
for paclitaxel and SB-T-1216, respectively (Figure 4C). It
was also a statistically significant increase. These data
demonstrate that MCF-7 cells grew even after application
of both taxanes at death-inducing concentrations when
caspase-2 expression was inhibited (Figure 4C).
Effect of the inhibition of caspase-2 expression on taxane
induced activation of caspase-8, -9, -3 and -7
Using siRNA technique (see “Materials and Methods”), we
also assessed the effect of specific inhibition of caspase-2
expression on the activation of caspase-8, -9,-3 and -7
after taxane application.
SK-BR-3 cells with suppressed expression of caspase-2
(for the efficiency see previous section) were incubated
with paclitaxel or SB-T-1216 (100nM) for 24 h. Subse-
quent western blot analysis showed significantly decreased
cleavage of caspase-9 and caspase-3 due to inhibition ofcaspase-2 expression. No considerable change in the level
of cleaved caspase-8 was observed. Surprisingly, the level
of cleaved caspase-7 significantly increased (Figure 5).
MCF-7 cells (without functional caspase-3) with in-
hibited expression of caspase-2 were incubated with tested
taxanes (300nM) for 48 h. Western blot analysis showed
significantly decreased levels of cleaved caspase-8 and
cleaved caspase-9. Decreased level of cleaved caspase-7
was not as pronounced (Figure 5).
Effect of taxanes on cellular distribution of caspase-2
The effect of tested taxanes on cellular distribution of
caspase-2 was assessed using confocal microscopy (see
“Materials and Methods”).
Confocal microscopy showed that caspase-2 (detected
by two different antibodies) seemed to be mainly found in
the nucleus of control SK-BR-3 cells. However, caspase-2
did not colocalize with DNA, as we demonstrated when
comparing interphase and mitotic control cells. After 36 h
of incubation with paclitaxel or SB-T-1216 at death-
inducing concentrations (100 nM), caspase-2 was released
from the nucleus to the cytosol. This was probably due to
the mitotic block following taxane application which is
associated with the disintegration of the nuclear envelope
SK-BR-3 MCF-7
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Figure 3 Effect of paclitaxel and SB-T-1216 on (A) the level of procaspase-2, cleaved caspase-2, and (B) the level of golgin-160 in
SK-BR-3 and MCF-7 cells. After 0, 12, 24, 36, 48 and 60 h of incubation with paclitaxel or SB-T-1216 (100 nM for SK-BR-3 cells and 300 nM for
MCF-7 cells), levels of procaspase-2, cleaved caspase-2 and levels of golgin-160 were determined using western blot analysis and relevant
antibodies (see “Materials and Methods”). Actin levels were used to confirm equal protein loading. The data shown were obtained in one
representative experiment of three (procaspase-2, cleaved caspase-2) or two (golgin 160) independent experiments. MCF-7 data demonstrating
the level of procaspase-2 and the level of cleaved caspase-2 are from different experiments.
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into mitochondria (data not shown). Similar data were
obtained with MCF-7 cells (data not shown).
Effect of taxanes on p53 activation
We assessed the activation of p53 by induction of
p21WAF1/CIP1 expression employing real-time PCR
(mRNA level) and western blot analysis (protein level).
Within 36-h incubation of SK-BR-3 cells (nonfunctional
p53) with paclitaxel at the death-inducing concentration
(100 nM), the level of p21WAF1/CIP1 mRNA decreased to
40% of the original value (statistically significant decrease).
Western blot analysis did not detect any p21WAF1/CIP1
protein in these cells during 36 h of incubation withthe taxane (Figure 7). Similar data were obtained with SB-
T-1216 in SK-BR-3 cells (data not shown).
With regard toMCF-7 cells (functional p53), p21WAF1/CIP1
mRNA level increased approximately 9-fold during 36 h of
incubation with paclitaxel at the death-inducing concen-
tration (300 nM). This pronounced and statistically signifi-
cant increase of p21WAF1/CIP1 mRNA level corresponded
to a pronounced increase in p21WAF1/CIP1 protein level
(Figure 7). Again, similar data were obtained with SB-T-1216
in these cells (data not shown).
Effect of taxanes on PIDD expression
Effect on PIDD expression was assessed using real-time PCR
(mRNA level) and western blot analysis (protein level).
Figure 4 Effect of the inhibition of caspase-2 expression on the growth and survival of SK-BR-3 and MCF-7 cells after paclitaxel and SB-
T-1216 treatment. (A) Efficiency of caspase-2 suppression by two employed specific siRNAs, i.e. A and B, in SK-BR-3 and MCF-7 cells is shown.
Levels of procaspase-2 were determined using western blot analysis and relevant antibodies (see “Materials and Methods”). Actin levels were used
to confirm equal protein loading. (B) Effect of nonsense siRNA and specific caspase-2 siRNA on the growth and survival of SK-BR-3 and MCF-7
cells without taxane treatment is also shown. (C) The effect of specific caspase-2 siRNA on the growth and survival of SK-BR-3 and MCF-7 cells
after taxane (T) treatment (100 nM for SK-BR-3 cells and 300 nM for MCF-7 cells) is presented. The cells were seeded at 7 × 103 cells/200 μl of
medium per well and prepared as described (see “Materials and Methods”). After 0, 48 and 96 h of incubation, the number of living cells was determined
(see “Materials and Methods”). Each column represents the mean of 4 separate cultures ± SEM. *P < 0.05, **P < 0.01 when comparing the effect.
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http://www.cancerci.com/content/13/1/42The level of PIDD mRNA showed a decrease (to 60% of
the original value) during 36-h incubation of SK-BR-3 cells
with paclitaxel at the death-inducing concentration (100
nM). PIDD protein level also seemed to decrease slightly
after 36 h of incubation with paclitaxel (Figure 8). Similar
data were obtained with SB-T-1216 (data not shown).PIDD mRNA in MCF-7 cells showed similar levels
during 36-h incubation with paclitaxel at the death-
inducing concentration (300 nM). No significant change
was found for PIDD protein level (Figure 8). As was the
case for SK-BR-3 cells, similar data were obtained with
SB-T-1216 (data not shown).
Figure 6 Effect of paclitaxel and SB-T-1216 on cellular distribution of caspase-2 in SK-BR-3 cells. Control cells were incubated without
taxane. After 36 h of incubation with tested taxane (100 nM), the localization of caspase-2 and DNA position were detected using confocal
microscopy, following staining with DAPI (DNA) and indirect immunofluorescence staining (caspase-2) with antibody against human caspase-2
(see “Materials and Methods”). The localization of caspase-2 (green), of DNA (blue) and the merge of caspase-2 and DNA within the cell are
shown. The data shown were obtained in one representative experiment of two independent experiments.
Figure 5 Effect of the inhibition of caspase-2 expression on the activation of caspase-8, -9, -3 and -7 in SK-BR-3 and MCF-7 cells after
paclitaxel and SB-T-1216 treatment. A specific caspase-2 siRNA (C2 siRNA) was used. Control cells were incubated without taxane and siRNAs.
Effects of nonsense siRNA as well as caspase-2 siRNA without taxane treatment are also shown. After 24 h (SK-BR-3) or 48 h (MCF-7) of incubation
with tested taxane (100 nM for SK-BR-3 cells and 300 nM for MCF-7 cells), levels of cleaved caspases were determined using western blot analysis
and relevant antibodies (see “Materials and Methods”). Actin levels were used to confirm equal protein loading. The data shown were obtained in
one representative experiment of two independent experiments.
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Figure 7 Effect of paclitaxel on the level of (A) p21WAF1/CIP1 mRNA and (B) p21WAF1/CIP1 protein in SK-BR-3 and MCF-7 cells. After 0, 12,
24 and 36 h of incubation with paclitaxel (100 nM for SK-BR-3 cells and 300 nM for MCF-7 cells), the level of mRNA was determined using RT-PCR
and relevant primers and the level of protein was determined using western blot analysis and relevant antibodies (see “Materials and Methods”).
Each column of mRNA data represents the mean of 4 experimental values ± SEM. *P < 0.05, **P < 0.01 when comparing the effect with that at
0 h. Actin levels of protein data were used to confirm equal protein loading. In the case of SK-BR-3 cells, MCF-7 cells after 36 h of incubation with
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Figure 8 Effect of paclitaxel on the level of (A) PIDD mRNA and (B) PIDD protein in SK-BR-3 and MCF-7 cells. After 0, 12, 24 and 36 h of
incubation with paclitaxel (100 nM for SK-BR-3 cells and 300 nM for MCF-7 cells), the level of mRNA was determined using RT-PCR and relevant
primers and the level of protein was determined using western blot analysis and relevant antibodies (see “Materials and Methods”). Each column
of mRNA data represents the mean of 4 experimental values ± SEM. *P < 0.05, **P < 0.01 when comparing the effect with that at 0 h. Actin levels
of protein data were used to confirm equal protein loading. The data shown were obtained in one representative experiment of three
independent experiments.
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levels were assessed using flow cytometric analysis
after staining with relevant primary and secondary
antibodies, for both cell lines (SK-BR-3 and MCF-7)
and both taxanes (paclitaxel and SB-T-1216) (data not
shown).Effect of taxanes on the coimmunoprecipitation of
caspase-2 and PIDD with RAIDD
Coimmunoprecipitation (see “Materials and Methods”) of
RAIDD protein with other components of PIDDosome,
i.e. PIDD protein and caspase-2, was assessed using subse-
quent western blot anylysis.
Both caspase-2 and PIDD protein (detected by anti-
body against C-form) were coimmunoprecipitated with
RAIDD protein after 24-h incubation of SK-BR-3 cells
with paclitaxel at the death-inducing concentration
(100nM) (Figure 9).
Similarly, caspase-2 and PIDD protein were detected
in coimmunoprecipitated complex with RAIDD protein
in MCF-7 cells after 24 h incubation with paclitaxel at
the death-inducing concentration (300 nM). Thus it
seems that PIDDosome is formed in both SK-BR-3 and
MCF-7 cells when taxane is applied at death-inducing
concentrations.Effect of the inhibiton of RAIDD expression on taxane
induced cell death
Employing RNA interference (see “Materials and
Methods”), we assessed the effect of specific inhibition
of RAIDD expression on cell death induction after
taxane application.
The inhibition of RAIDD expression by RNA interfer-
ence was found to be highly efficient for both SK-BR-3Figure 9 Effect of paclitaxel on coimmunoprecipitation of caspase-2 a
incubation with paclitaxel (100 nM for SK-BR-3 cells and 300 nM for MCF-7
caspase-2 as well as PIDD (detected by antibody against C-form) were dete
(see “Materials and Methods”). The heavy chain of the antibody used for RA
independent experiments.and MCF-7 cells (Figure 10A). Specific RAIDD siRNA
did not significantly affect cell growth or survival in
ether cell line (data not shown).
After 48 h as well as 96 h of incubation with paclitaxel
at death-inducing concentration (100 nM), the inhib-
ition of RAIDD expression did not result in any signifi-
cant change in the number of surviving SK-BR-3 cells
(Figure 10B).
Similarly for MCF-7 cells, the inhibition of RAIDD ex-
pression did not result in any significant change in the
number of surviving cells after 48 h and 96 h of incuba-
tion with paclitaxel at death-inducing concentration
(300 nM) (Figure 10B).
Discussion
In our previous studies [7,14], we demonstrated that
caspase-2 was significantly activated (up to 20-fold) along
with other caspases (caspase-3, caspase-9 and caspase-8)
during apoptosis induction by taxanes in some cancer
cells. We have also shown that, at least in some cases, the
mitochondrial pathway does not represent the main path-
way of apoptosis induction by taxanes. Recently, we found
that apoptosis was induced by taxane application in SK-
BR-3 and MCF-7 breast cancer cells and that caspase-2
was also significantly activated in these cells. Furthermore,
MCF-7 cells are without functional caspase-3, as we con-
firmed (data not shown). Thus it is reasonable to assume
that caspase-2 could play an important role in apoptosis
induction by taxanes in breast cancer cells.
In order to study the role of caspase-2 in apoptosis in-
duction by taxanes in breast cancer cells, we employed
a convenient model using SK-BR-3 and MCF-7 cells. SK-
BR-3 cells have nonfunctional p53 and functional caspase-
3 [39]. On the other hand, MCF-7 cells have functional
p53, but they do not have functional caspase-3 [40]. Thend PIDD with RAIDD in SK-BR-3 and MCF-7 cells. After 24 h of
cells), the level of precipitated RAIDD and coimmunoprecipitated
rmined using western blot analysis and relevant antibodies
IDD precipitation (Ab) is seen. The data shown were obtained in two
Figure 10 Effect of the inhibition of RAIDD expression on the growth and survival of SK-BR-3 and MCF-7 cells after paclitaxel
treatment. (A) Efficiency of RAIDD suppression by two employed specific siRNA, i.e. A and B, in SK-BR-3 and MCF-7 cells is shown. Levels of
RAIDD were determined using western blot analysis and relevant antibodies (see “Materials and Methods”). Actin levels were used to confirm
equal protein loading. (B) The effect of specific RAIDD siRNA on the growth and survival of SK-BR-3 and MCF-7 cells after paclitaxel (T) treatment
(100 nM for SK-BR-3 cells and 300 nM for MCF-7 cells) is presented. The cells were seeded at 7 × 103 cells/200 μl of medium per well and
prepared as described (see “Materials and Methods”). After 0, 48 and 96 h of incubation, the number of living cells was determined (see “Materials
and Methods”). Each column represents the mean of 2 separate cultures ± SEM.
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could help to elucidate the role of caspase-2 in apoptosis
induction by taxanes. It could particularly contribute
to our knowledge concerning the relationship between
caspase-2 activation and the activation of other caspases
as well as the mechanism of caspase-2 activation itself.
We tested both a classical taxane paclitaxel and a
novel (second-generation) taxane SB-T-1216. In our pre-
vious study with MDA-MB-435 and NCI/ADR-RES cell
lines [14], SB-T-1216 was shown to be more effective
than paclitaxel, particularly in NCI/ADR-RES cells re-
sistant to paclitaxel. However, SB-T-1216 and paclitaxel
seemed to use the same or similar mechanism of cell
death induction [7,14]. In this study, MCF-7 cells were
shown to be a slightly more resistant to taxanes than
SK-BR-3 cells but both cell lines showed similar sensitiv-
ity to paclitaxel and SB-T-1216 (see Figure 1). Further-
more, it seems that paclitaxel and SB-T-1216 use the
same mechanism of apoptosis induction (see Figures 2,
3, 4, 5, 6 and “Results”).
Significant activation of caspase-2 in SK-BR-3 and
MCF-7 cells after taxane application at death inducing
concentrations (see Figure 2) was confirmed using several
different methods (see Figure 3). It is known that the
measurement of caspase-2 activity can be affected by the
activity of caspase-3 [41]. Thus, the measured activity ofcaspase-2 (see Figure 2) can be in fact a sum of caspase-2
and caspase-3 activities. It can explain the discrepancy in
timing of measured caspase-2 activity (see Figure 2) and
detected caspase-2 activation (see Figure 3). In MCF-7
cells, we only detected cleavage of procaspase-2 (see
Figure 3A) under different conditions than procaspase-2
was detected. However, the problem of detecting the
cleaved form of caspase-2 in MCF-7 cells could be a spe-
cific feature of these cells as described previously [42].
With regard to other cell types, several studies have dem-
onstrated caspase-2 activation in various types of cancer
cells after apoptosis induction by taxanes [37,38,43].
Several studies with human prostate cancer cells, human
melanoma cells and mouse embryonic fibroblasts have
shown that caspase-2 is required for apoptosis induction
by taxanes. These studies employed various techniques
using siRNA, caspase-2-/- cells and specific caspase-2 in-
hibitors [21,23,44]. We also demonstrated that caspase-2
is required, at least partially, for apoptosis induction by
taxanes in both studied breast cancer cell lines. The inhib-
ition of caspase-2 expression using siRNA technique
resulted in a significantly increased number of surviving
cells following application of taxanes at death-inducing
concentrations. MCF-7 cells, with inhibited caspase-2
expression, grew even after application of death-inducing
concentrations of taxanes (see Figure 4). This effect could
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cation on cell proliferation (see Figure 4B).
In spite of the fact that several studies have shown the
involvement of caspase 2 in apoptosis induction by vari-
ous stimuli in breast cancer cells [27,34,35], the mecha-
nism of caspase-2 involvement in apoptosis induction is
not fully understood. Caspase-2 has been described as an
apical caspase [21,23] as well as a possible executioner
caspase [45], in various types of cancer cells, together with
its functions which are independent of apoptosis [46,47].
In this study with SK-BR-3 and MCF-7 cells we demon-
strated that, together with caspase-2, other caspases
(caspase-8, caspase-9, caspase-3, caspase-7) were activated
after application of taxanes.
The activation of caspase-9, -3 and -7 was significantly
affected in SK-BR-3 cells with inhibited caspase-2 ex-
pression after cell death induction by taxane application.
While the cleavage of caspase-9 and caspase-3
significantly decreased, caspase-7 cleavage increased.
In MCF-7 cells (without functional caspase-3) the cleav-
age of caspase-9 was nearly blocked and the cleavage of
caspase-7 was significantly decreased. Cleavage of
caspase-8 decreased slightly in SK-BR-3 cells and sig-
nificantly in MCF-7 cells (see Figure 5). The substantial
inhibitory effect of the inhibition of caspase-2 expres-
sion on the activation of caspase-8 and caspase-9, as
well as the activation of executioner caspase-3 in SK-BR-3
cells and executioner caspase-7 in MCF-7 cells, supports a
suggestion that caspase-2 functions as an apical caspase.
The increase of caspase-7 activation together with the
decrease of caspase-3 activation, due to the inhibition of
caspase-2 expression, in SK-BR-3 cells seems rather ob-
scure (see Figure 5). Some kind of compensatory mechan-
ism could be involved.
Additional information concerning caspase-2 function
could come from testing the cleavage of caspase-2
substrates. However, there are only a few known specific
substrates of caspase-2 such as golgin-160 [31,46]. In
this study, we demonstrated golgin-160 cleavage after
application of death-inducing taxane concentrations in
both studied cell lines (see Figure 3B). Unfortunately, it
was not very helpful in elucidating caspase-2 function
without data connecting golgin-160 cleavage to other
relevant events.
Caspase-2 has been found in the cytosol, Golgi com-
plex, mitochondria and also in the nucleus of cells [46].
Regarding SK-BR-3 and MCF-7 cells, we showed that
caspase-2 seemed to be primary localized in the nucleus.
However, caspase-2 did not colocalize with DNA, as
demonstrated with mitotic cells. Treating the cells with
death-inducing taxane concentrations seemed to lead to
a redistribution of caspase-2 from the nucleus to the
cytosol (see Figure 6). Caspase-2 was probably released
from the nucleus because of the long-term disintegration ofthe nuclear envelope associated with the mitotic block after
application of taxanes. The question, whether caspase-2 is
activated within the nucleus or in the cytoplasm, has not
been answered yet [47]. In our case, long-term exposure of
most of the cellular caspase-2 to the cytoplasmic environ-
ment, which can comprise caspase-2-activating capacity,
could lead to caspase-2 activation. Thus, there could be a
very simple explanation for caspase-2 activation in breast
cancer cells after taxane application.
Caspase-2 activation is usually connected with
PIDDosome formation and PIDD protein upregulation
via the induction of expression by activated p53 [23-25].
We found significant p53 activation assessed by the induc-
tion of p21WAF1/CIP1 expression, after the application of
death-inducing taxane concentration in MCF-7 cells with
functional p53 [48]. On the other hand, in SK-BR-3 cells
without functional p53 [39] we confirmed that there was
no p53 activity (see Figure 7). In the next step, we assessed
the effect of taxanes on PIDD expression. No significant
effect of taxanes on PIDD upregulation was found in
either SK-BR-3 or MCF-7 cells (see Figure 8). This means
that p53 activation, and the subsequent PIDD upregu-
lation, is not involved in caspase-2 activation.
Nevertheless, we detected some coimmunoprecipitation
of RAIDD protein with both PIDD protein and caspase-2
in both cell lines 24 h after taxane application at the
death-inducing concentrations. However, suprisingly the
inhibition of RAIDD expression using siRNA technique
did not affect the number of surviving SK-BR-3 as well as
MCF-7 cells after taxane application at all. Therefore, we
suggest that PIDDosome formation [49] does not repre-
sent the main platform for caspase-2 activation in breast
cancer cells when apoptosis is induced by taxanes. Re-
cently, other pathways of caspase-2 activation which cir-
cumvent PIDDosome formation have been reported [50],
e.g. the activation of caspase-2 in DISC complex [51].
Therefore other pathways of caspase-2 activation in cells
treated with taxanes should be considered.
Conclusions
We can summarize that significant caspase-2 activation
is associated with apoptosis induction by taxanes in
tested breast cancer cells and that caspase-2 is required,
at least partially, for the induction as well. Caspase-2
could be activated due its release from the nucleus and
subsequent long-term exposure to the cytoplasmic en-
vironment after taxane application resulting in long-
term disintegration of the nuclear envelope. Concerning
the mechanism of caspase-2 activation, caspase-2 seems
to be activated via other mechanism than PIDDosome
formation. The activation of both initiator and executioner
caspases after taxane application depends on caspase-2 ex-
pression. Thus we can suggest that caspase-2 functions as
an apical caspase in apoptosis induction by taxanes.
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Materials
Paclitaxel was obtained from Sigma-Aldrich (St. Louis,
MO, USA). SB-T-1216 [13] was synthesized at the Institute
of Chemical Biology and Drug Discovery (Stony Brook,
NY, USA). Taxanes were dissolved in DMSO (tissue cul-
ture quality) to obtain a 1 mM stock solution.
For western blot analysis, the following primary antibodies
were used: mouse monoclonal antibody against caspase-3
(#9668), rabbit antibody against cleaved caspase-3 (#9661),
rabbit antibody against cleaved caspase-7 (#9491), mouse
monoclonal antibody against caspase-8 (#9746), and rabbit
antibody against cleaved caspase-9 (#9505) from Cell Signa-
ling Technology (Danvers, MA, USA), rat monoclonal anti-
body against caspase-2 (ALX-804-355-C100) and mouse
monoclonal antibody against PIDD (ALX-804-837) from
Enzo Life Science (Farmingdale, NY, USA), rabbit monoclo-
nal antibody against caspase-2 (ab32021), rabbit polyclonal
antibody against caspase-2 (ab 18737), goat polyclonal
antibody against golgin-160 (anti-GOLGA3, ab40837), and
rabbit monoclonal antibody against RAIDD (Ab52621)
from Abcam (Cambridge, UK), rabbit polyclonal antibody
against caspase-2 (H-145, sc-15379), mouse monoclonal
antibody against p21 (F-5, sc-6246), goat polyclonal anti-
body against PIDD (S-17, sc-32161), and rabbit polyclonal
antibody against PIDD (H-300, sc-2354) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), and mouse mono-
clonal antibody against actin (AC-40, A3853) from Sigma-
Aldrich.
For precipitation, Protein A/G PLUS- agarose beads
(sc-2003) from Santa Cruz Biotechnology were used.
Cells and culture conditions
Human breast carcinoma cell lines SK-BR-3 and MCF-7
were obtained from American Type Culture Collection
(ATCC) (Rockville, MD, USA) and National Cancer Insti-
tute (Frederick, MD, USA). The cells were maintained in a
culture medium at 37°C in a humidified atmosphere of
5% CO2 in air. The culture medium consisted of basic
medium supplemented with 10% heat-inactivated fetal
bovine serum (Biochrom AG, Berlin, Germany). The basic
medium was RPMI 1640 medium (Sigma-Aldrich, St. Louis,
MO, USA) containing extra L-glutamine (300 μg/ml), so-
dium pyruvate (110 μg/ml), HEPES (15 mM), penicillin
(100 U/ml) and streptomycin (100 μg/ml), as previously
described [52].
Assessment of cell growth and survival
Cells were harvested and seeded at 20 × 103 cells/100 μl
of culture medium into the wells of a 96-well plastic
plate. After 24-h preincubation period allowing cells to
attach, the culture medium was replaced by either the
culture medium without taxane (control) or with one of
tested taxanes (paclitaxel or SB-T-1216) at desiredconcentrations. Cell growth and survival were evaluated
after 96 h of incubation. The number of living cells was
determined using a hemocytometer after staining with
trypan blue [53].
Measurement of caspase-2 activation
A commercial CaspGLOW™ Active Caspase Staining Kit
(Biovision, Mountain View, CA, USA) was used to de-
tect the active form of caspase-2, as previously described
[54]. Cells (approximately 3 × 105 cells per sample) were
seeded and after a 24-h preincubation period allowing
cells to attach, the culture medium was replaced by
either taxane-free culture medium (control) or with
medium containing taxane (paclitaxel or SB-T-1216) at
desired concentrations. After the required incubation
period, the cells were harvested using low-speed centri-
fugation and staining was performed according to the
manufacturer’s instructions. Fluorescence was measured
using a FACS Calibur cytometer (Becton Dickinson, San
Jose, CA, USA).
Real-time PCR
Cells were harvested and seeded at 1.2 × 106 cells/6 ml
of the culture medium into Petri dishes. After a 24-h
preincubation period, the culture medium was either re-
placed by taxane-free culture medium (control) or with
medium containing taxane (paclitaxel or SB-T-1216) at
desired concentrations. Total RNA was isolated from
SK-BR-3 and MCF-7 cells using a RNAeasy MiniKit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions after the required incubation period.
Prepared RNA was reverse transcribed using a TaqMan
Reverse Transcription Reagents kit (Applied Biosystems,
Foster City, CA, USA) with random primers, in accord-
ance with the manufacturer’s instructions. Transcribed
cDNA was subjected to real-time quantitative PCR in an
ABI Prism 7000 Sequence Detection System (Applied
Biosystems) using a commercially available TaqMan Gene
Expression Master Mix kit (Applied Biosystems) with
TaqMan Gene Expression Assays (Applied Biosystems) for
CDKN1A (cyclin-dependent kinase inhibitor 1A, p21),
PIDD (p53-induced death domain protein), CASP2
(caspase-2) and for GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) as the control gene. All data were normal-
ized relative to the amount of GAPDH cDNA in the sam-
ple and the 2−ΔΔCt method was used to calculate relative
changes in genes expression using ABI Prism 7000 SDS
Software Version 1.1 (Applied Biosystems).
Western blot analysis
Cells (approximately 1 × 107 cells per sample) were seeded
and taxanes were applied after 24-h preincubation. Cells
were harvested after the incubation period by low-speed
centrifugation, washed in PBS and centrifuged. Cell pellets
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RIPA buffer (Sigma Aldrich, St. Louis, MO, USA) con-
taining a mixture of protease inhibitors (Sigma Aldrich).
The protein lysate was centrifuged (14,000 rpm, 20 min,
4°C) and the supernatant was stored at -20°C.
Western blot was carried out with some modifications
as has been previously described in detail [4]. Proteins
separated by SDS-PAGE were blotted onto 0.2 μm nitro-
cellulose membrane PROTRAN BA 83, (Whatman-
Schleicher and Schuell, Maidstone, UK) for 3 h at 0.25
A, using a MiniProtean II blotting apparatus (Bio-Rad,
Hercules, CA). The membrane was blocked with 5%
nonfat milk or 5% BSA in TBS for 15 min. TBS
containing Tween-20 (0.1%) was used for washing. The
washed membrane was incubated with the primary anti-
body. Following incubation (overnight, 4°C), the mem-
brane was washed (three times) and then incubated for
1–2 h with the corresponding horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Afterward, the membrane
was washed three times and the chemiluminescence
signal was detected using a Supersignal West Pico
Chemiluminescence Substrate from Pierce (Thermo
Fisher Scientific Inc., Rockford, IL, USA) and and the
KODAK Gel Logic 1500 Imaging System (Eastman Kodak
Company, Rochester, NY, USA).
RNA interference
In order to optimize the RNA interference procedure,
two independent siRNAs targeting the caspase-2 mRNA
sequence, i.e. MISSION® esiRNA human CASP2 (Sigma
Aldrich, St. Louis, MO, USA) and CASP2 siRNA
(s2412, Applied Biosystems, Foster City, CA, USA), and
two independent siRNA targeting the RAIDD mRNA
sequence, i.e. two CRADD (RAIDD) Silencer® Select
siRNAs (s16654 and s225028, Applied Biosystems,
Foster City, CA, USA), were tested. Two different trans-
fection agents, i. e. INTERFERin™ (Polyplus transfection™,
Illkirch, France) and siPORT™ NeoFX™ Transfection
Agent (Applied Biosystems) were also tested. We used
GAPDH siRNA (Applied Biosystems) as a positive trans-
fection control and Silencer® Negative Control siRNA
(Applied Biosystems) as the non-targeting siRNA. The
efficiency of caspase-2 and RAIDD inhibition was tested
after 48-h incubation of cells with a medium containing
transfection mixture for mRNA levels (real-time PCR,
data not shown) and after 72-h incubation for protein
levels (western blot analysis, Figure 4A). The efficiency of
caspase-2 and RAIDD inhibition reached similar levels
using any combination of the two tested transfection agents
and the two siRNAs. For experiments, INTERFERin™
transfection agent (Polyplus transfection™), CASP2 siRNA
(Applied Biosystems) and CRADD (RAIDD) siRNA
s225028 (Applied Biosystems) were used.Based on the manufacturer’s instructions (INTERFERin™
in vitro siRNA Transfection Protocol, Polyplus transfec-
tion™) we performed RNA interference in SK-BR-3 and
MCF-7 cells. The cells were seeded at 7 × 103 cells/200 μl
of culture medium into a 96-well plate or at 7 × 104 cells/
2 ml of culture medium into a12-well plate for 24-h
preincubation. The siRNA was diluted in OPTI-MEM® I
Reduced Serum Medium (Gibco, Invitrogen™ Life Tech-
nologies, Carlsbad, CA, USA) for a final concentration of
5 nM siRNA. INTERFERin™ transfection agent (0.75 μl
per 96-well and 4 μl per 12-well) was added. The mixture
was incubated for 10 min at room temperature to form
the transfection complex. Preincubation medium in wells
was replaced by fresh culture medium (150 μl in 96-well
plates and 1 ml in 12-well plates). Prepared transfection
complex was added to fresh culture medium in cultivation
wells and gently mixed. Cells were incubated with the
medium containing transfection complex for 72 h. After
incubation, the medium containing transfection complex
was replaced with the culture medium containing tested
taxane at the death inducing concentration for further
analyses.
Confocal microscopy
Cells were seeded onto coverslips (approximately 2 × 105
cells per coverslip) and taxanes were applied after 24 h of
preincubation as described above (see “Measurement
of caspase-2 activation”). After 36 h of incubation for SK-
BR-3 and 60 h of incubation for MCF-7, cells were fixed
with 4% paraformaldehyde for 15 min at 37°C and perme-
abilized with 0.1% Triton X-100 in 4% paraformaldehyde
for 15 min. After washing with PBS, cells were blocked
with Image-iT™ FX signal enhancer (Molecular Probes,
Invitrogen, Eugene, OR, USA) for 30 min. Next, cells were
washed with PBS and stained with 30 μl of the primary
antibody against caspase-2 (H-145, Santa Cruz Bio-
technology, Santa Cruz, CA, USA or ab18737, Abcam,
Cambridge, UK), diluted 1:50 in PBS, at 4°C overnight.
Cells were than washed with PBS and incubated with
30 μl of Alexa Fluor® 488 goat anti-rabbit secondary anti-
body (Molecular Probes), diluted 1:200 in PBS, for 1 hour
in a dark at room temperature. Finally, cells were washed
again with PBS. Stained cells on coverslips were transferred
onto a droplet of Vectashield® Mounting Medium with
DAPI (Vector Laboratories, Burlingame, CA, USA) and
sealed. Samples were analyzed using a Leica TCS SP5 con-
focal microscope (Bannockburn, IL, USA) using a 63× oil
objective at relevant excitation and emission wavelengths.
Immunoprecipitation
First, 25 μl of agarose beads coated with bacterial pro-
teins A and G (sc-2003) from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) were washed (resuspended in
0.5 ml of lysis buffer and centrifuged at 5000 rpm,
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lysis buffer. 3.3 μl of anti-RAIDD (see “Materials”) anti-
body was added to the beads and mixture was incubated
for 4 h in a refrigerator. Beads with bound antibody were
washed as described and supernatant was removed.
Beads with bound antibody were stored at 4°C.
Cell were harvested (see “Western blot analysis”) and
lysed by non-denaturing lysis buffer (1% NP-40, 20 mM
TRIS pH 7.4, 1 mM EDTA, 5% glycerol, 250 mM NaCl).
Cell lysates were incubated for 20 min on ice and then
centrifuged (14, 000 rpm, 15 min.) at 4°C. Supernatants
containing cell proteins were stored on ice and protein
concentrations were assessed.
Beads with bound antibody were diluted (to final vol-
ume of 100 μl) in lysate buffer containing 300 μg of cell
proteins. The mixture was incubated overnight while ag-
itated. After incubation, the mixture was centrifuged
(6500 rpm, 7 min) and supernatant was discarded. Beads
with bound immunocomplexes were washed twice as de-
scribed with lysis buffer and twice with 50 mM Tris HCl
pH 7.5. Washed beads with bound immunocomplexes
were finally resuspended in 40 μl of sample buffer (see
“Western blot analysis”) and heated for 15 min at 75°C to
disintegrate the beads and release the immunocomplexes.
15 μl of the samples were loaded on 15% polyacrylamide
gel for Western blot analysis (see “Western blot analysis”).
Statistical analysis
Statistical significance of difference was determined using
the Student’s t-test. P < 0.05 and P < 0.01 were considered
statistically significant at the 5% and 1% levels, respectively.
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